JP2008530110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530110A5 JP2008530110A5 JP2007555236A JP2007555236A JP2008530110A5 JP 2008530110 A5 JP2008530110 A5 JP 2008530110A5 JP 2007555236 A JP2007555236 A JP 2007555236A JP 2007555236 A JP2007555236 A JP 2007555236A JP 2008530110 A5 JP2008530110 A5 JP 2008530110A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- lack
- effective amount
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 210000002374 sebum Anatomy 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 230000037393 skin firmness Effects 0.000 claims 2
- 230000037067 skin hydration Effects 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 206010031240 Osteodystrophy Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- -1 t-butyldimethylsilyl groups Chemical group 0.000 claims 1
- XPJAYNDSNNJWDA-AWCUZLSVSA-N C[C@H]([C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O)/C=C/[C@@H](C(C)(C)O)C=[IH] Chemical compound C[C@H]([C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O)/C=C/[C@@H](C(C)(C)O)C=[IH] XPJAYNDSNNJWDA-AWCUZLSVSA-N 0.000 description 2
- 0 C[C@](C(CC1)[C@@](C)(CCC2)[C@@]1C2=CC=C(C[C@@](*)C1=C)C[C@]1*#C)C=C[C@](*)C(C)(C)* Chemical compound C[C@](C(CC1)[C@@](C)(CCC2)[C@@]1C2=CC=C(C[C@@](*)C1=C)C[C@]1*#C)C=C[C@](*)C(C)(C)* 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65247305P | 2005-02-11 | 2005-02-11 | |
| US60/652,473 | 2005-02-11 | ||
| PCT/US2006/004699 WO2006086613A2 (en) | 2005-02-11 | 2006-02-10 | 2-METHYLENE-19-NOR- (20S-24S) - 1α, 25-D IHYDROXYVITAMIN-D2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008530110A JP2008530110A (ja) | 2008-08-07 |
| JP2008530110A5 true JP2008530110A5 (enExample) | 2009-03-05 |
| JP5036566B2 JP5036566B2 (ja) | 2012-09-26 |
Family
ID=36793746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555236A Expired - Fee Related JP5036566B2 (ja) | 2005-02-11 | 2006-02-10 | ２−メチレン−１９−ノル−（２０Ｓ−２４Ｓ）−１α，２５−ジヒドロキシビタミン−Ｄ２ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7563783B2 (enExample) |
| EP (1) | EP1853274B1 (enExample) |
| JP (1) | JP5036566B2 (enExample) |
| AU (1) | AU2006213727B2 (enExample) |
| CA (1) | CA2597624C (enExample) |
| ES (1) | ES2404061T3 (enExample) |
| MX (1) | MX2007009726A (enExample) |
| WO (1) | WO2006086613A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060079490A1 (en) * | 2001-01-25 | 2006-04-13 | Deluca Hector F | Method of treatment of type I diabetes |
| NZ545862A (en) * | 2003-08-20 | 2010-01-29 | Wisconsin Alumni Res Found | 2-Methylene-19-nor-vitamin D2 compounds |
| AU2007300214A1 (en) * | 2006-09-28 | 2008-04-03 | Wisconsin Alumni Research Foundation | 2-methylene-(20R,25S)-19,27-dinor-(22E)-vitamin D analogs |
| CA2764577C (en) * | 2009-08-03 | 2017-12-19 | Wisconsin Alumni Research Foundation | Method of preventing renal disease and treating symptoms thereof |
| EP2525799B1 (en) * | 2009-10-02 | 2014-09-03 | Wisconsin Alumni Research Foundation | (20s,22e)-2-methylene-19-nor-22-ene-1alpha,25-dihydroxyvitamin d3 analogs |
| US20110237557A1 (en) * | 2010-03-23 | 2011-09-29 | Deluca Hector F | Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3 |
| US8664206B2 (en) | 2010-03-23 | 2014-03-04 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 |
| US8604009B2 (en) * | 2010-03-23 | 2013-12-10 | Wisconsin Alumni Research Foundation | (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3 |
| CA2824870C (en) * | 2011-06-14 | 2018-08-14 | Wisconsin Alumni Research Foundation | 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses |
| HK1206600A1 (en) | 2012-06-29 | 2016-01-15 | Wisconsin Alumni Research Foundation | USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM |
| US10369161B2 (en) | 2014-12-30 | 2019-08-06 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism |
| US9539264B2 (en) | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588716A (en) * | 1984-05-04 | 1986-05-13 | Wisconsin Alumni Research Foundation | Method for treating metabolic bone disease in mammals |
| US4666634A (en) * | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
| US5086191A (en) * | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
| JP2898882B2 (ja) * | 1993-04-05 | 1999-06-02 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物 |
| US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
| US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US5945410A (en) * | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| US6673782B2 (en) * | 1999-04-29 | 2004-01-06 | Wisconsin Alumni Research Foundation | Treatment of systemic lupus erythematosis |
| US6479474B2 (en) * | 1999-07-08 | 2002-11-12 | Wisconsin Alumni Research Foundation | Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis |
| US6384087B1 (en) * | 2000-09-01 | 2002-05-07 | University Of Tennesseee Research Corporation, Inc. | Materials and methods for the treatment or prevention of obesity |
| US7704979B2 (en) * | 2000-09-01 | 2010-04-27 | The University Of Tennessee Research Foundation | Materials and methods for the treatment or prevention of obesity |
| AU7544501A (en) * | 2000-09-08 | 2002-03-22 | Wisconsin Alumni Res Found | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| US6627622B2 (en) * | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| US6566352B1 (en) * | 2002-02-18 | 2003-05-20 | Wisconsin Alumni Research Foudation | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| ATE346839T1 (de) * | 2002-03-29 | 2006-12-15 | Wisconsin Alumni Res Found | Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacal iferol |
| US7259143B2 (en) * | 2002-09-05 | 2007-08-21 | Wisconsin Alumni Research Foundation | Method of extending the dose range of vitamin D compounds |
| NZ542674A (en) * | 2003-04-10 | 2009-03-31 | Wisconsin Alumni Res Found | 2-Propylidene-19-nor-vitamin D compounds |
| NZ545862A (en) * | 2003-08-20 | 2010-01-29 | Wisconsin Alumni Res Found | 2-Methylene-19-nor-vitamin D2 compounds |
| CA2539361A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| CA2539357A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
| WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
| WO2005051396A2 (en) * | 2003-11-25 | 2005-06-09 | Deltanoid Pharmaceuticals, Inc. | Methods for reducing body fat using vitamin d compounds |
-
2006
- 2006-02-10 CA CA2597624A patent/CA2597624C/en not_active Expired - Fee Related
- 2006-02-10 MX MX2007009726A patent/MX2007009726A/es active IP Right Grant
- 2006-02-10 US US11/352,454 patent/US7563783B2/en not_active Expired - Fee Related
- 2006-02-10 AU AU2006213727A patent/AU2006213727B2/en not_active Ceased
- 2006-02-10 EP EP06720601A patent/EP1853274B1/en not_active Not-in-force
- 2006-02-10 WO PCT/US2006/004699 patent/WO2006086613A2/en not_active Ceased
- 2006-02-10 ES ES06720601T patent/ES2404061T3/es active Active
- 2006-02-10 JP JP2007555236A patent/JP5036566B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520689A5 (enExample) | ||
| JP2008530110A5 (enExample) | ||
| JP2005529878A5 (enExample) | ||
| JP2009532458A5 (enExample) | ||
| JP2010540555A5 (enExample) | ||
| JP2013500986A5 (enExample) | ||
| JP2008520703A5 (enExample) | ||
| TWI598098B (zh) | 脂質異常症治療劑 | |
| IL176707A0 (en) | New compounds, methods for their preparation and use thereof | |
| JP2010540556A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| JP2011506274A5 (enExample) | ||
| JP2005533835A5 (enExample) | ||
| JP2008530109A5 (enExample) | ||
| JP2007502805A5 (enExample) | ||
| JP2008520705A5 (enExample) | ||
| CN109843338A (zh) | 含有psma抑制剂的18f标记的三唑 | |
| JP2008520708A5 (enExample) | ||
| JP2010504995A5 (enExample) | ||
| WO2015128492A1 (en) | Monomethyl- and dimethylfumarate for nk cell activation | |
| JP2007504168A5 (enExample) | ||
| CA2597624A1 (en) | 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2 | |
| JP2010500284A5 (enExample) | ||
| JP2011527695A5 (enExample) | ||
| JP2013522369A5 (enExample) |